Meta-Analysis of Clinical Efficacy and Safety of Tripterygium wilfordii Polyglycosides Tablets in the Treatment of Chronic Kidney Disease

Table 1

Basic information and quality evaluation results included in the literature.

Author	Year	Disease	Included in the study			Follow-up time (mo)	Course of disease (y)	Intervention measures
			T/C	M/F	Age (y)			T	C
Tan Wei [15]	2014	NS	15/15	20/10	28.5 ± 3.5	6–12	1.13	TG	Glucocorticoid
Li Peng [16]	2018	NS	30/30	33/27	48.62 ± 1.41/48.63 ± 11.25	6	1.52 ± 1.41/1.65 ± 1.47	TG	Prednisone
Luo Minghua [17]	2018	NS	48/48	56/40	51.6 ± 10.3/51.2 ± 10.1	6	5.1 ± 1.9/4.9 ± 1.7	TG	Prednisone
Shi Qingwan [18]	2018	NS	50/50	—	49 ± 6.9/47 ± 5.7	6	19 ± 6.7/18 ± 5.7	TG	Prednisone acetate
Guo Peng [19]	2016	NS	40/40	43/37	45.7 ± 2.1/45.5 ± 3	3	8.2 ± 1/7.5 ± 1.2	TG	CTX
Song Bo [20]	2018	NS	36/35	38/33	50.26 ± 9.27/48.68 ± 9.38	6	14.53 ± 6.35/13.28 ± 6.13	TG	Prednisone
Ye Lan [21]	2015	NS	30/30	42/18	33.9 ± 3.8	18–24	—	TG	Methylprednisolone + dipyridamole
Chang Xuejing [22]	2013	NS	41/41	66/22	34.9 ± 3.9	18–24	—	TG	Methylprednisolone + dipyridamole
Deng Shuntian [23]	2017	NS	36/36	43/29	48.2 ± 2.5/47.6 ± 2.4	8	3.9 ± 1.9/3.8 ± 1.2	TG	Prednisone acetate + CTX
Jiang Xiaoli [24]	2014	NS	31/31	38/24	66.7 ± 4.2/64.3 ± 4.5	6	8 ± 4.1/8.7 ± 4.5	TG	Methylprednisolone
Jiang Chunxia [25]	2016	NS	24/24	27/21	56.07 ± 6.97/54.27 ± 6.26	—	—	TG	Methylprednisolone
LiaoWen [26]	2016	NS	56/56	57/55	70.2 ± 5.6/70.5 ± 5.4	6	0.8 ± 0.38/0.79 ± 0.4	TG	Methylprednisolone
Wan Danguo [27]	2020	NS	60/60	36/24	69.43 ± 3.74	6	3.52 ± 0.94	TG	Methylprednisolone
Zhang Liyang [28]	2019	NS	44/44	47/41	41.11 ± 7.24/41.05 ± 7.05	12	3.18 ± 1.08/3.25 ± 1.02	TG	Methylqiangdisong
Deng Minghua [29]	2014	NS	23/23	21/25	31.6 ± 6.9/35.2 ± 8.7	2	—	TG	Sufficient prednisone
Zhou Zhaoxie [30]	2018	NS	45/45	50/40	52.5 ± 6.5/52.3 ± 6.3	12	3.2 ± 1.1/3.2 ± 1	TG	Prednisone
Niu Hejun [31]	2015	NS	20/20	24/16	62.71 ± 9.13	12	0.25–10	TG	Prednisone
Zhang Peiguang [32]	2019	NS	25/25	28/22	39.87 ± 5.21/39.94 ± 5.23	6	1.57 ± 0.22	TG	Basics + prednisone acetate
Yan Lingzhi [33]	2014	NS	30/30	38/22	45.2 ± 18.3/43.8 ± 14.3	3	10.8 ± 3.5/6.9 ± 3.1	TG	CTX
Chen Fang [34]	2012	NS	50/50	46/54	23–66	3–6	0.5–12	TG	CTX
Liu Qian [35]	2017	NS	41/41	53/29	39.5 ± 8.6/38.9 ± 8.5	6	2.9 ± 1.1/2.8 ± 1.3	TG	Prednisone
Gao Xiaofeng [36]	2019	NS	42/42	34/50	36.74 ± 6.28/37.18 ± 6.94	6	0.94 ± 0.39/1.01 ± 0.44	TG	Basics + MMF
Ni Ying [37]	2017	NS	60/60	51/69	40.2 ± 8.3/38.5 ± 7.3	6	1.12 ± 0.71/1.05 ± 0.68	TG	MMF
Zhao Jingyu [38]	2018	NS	36/36	39/33	37.77 ± 5.42/37.68 ± 5.35	6	1.61 ± 0.27/1.58 ± 0.24	TG	Basic + prednisone acetate
Wu Wensheng [39]	2019	NS	42/42	41/43	51.06 ± 4.18/50.28 ± 4.12	6	1.64 ± 0.86/1.56 ± 0.85	TG	Regular + prednisone
Xiong Xinrong [40]	2019	NS	40/40	45/35	64.1 ± 3.5/63.2 ± 4.2	3–6	5.1 ± 1.5/5.2 ± 1.3	TG	Prednisone
Liu Fan [41]	2017	NS	64/64	73/55	52.39 ± 12.37/51.82 ± 13.86	6	1.62 ± 0.68/1.55 ± 0.69	TG	Prednisone
Zhang Zhifang [42]	2015	NS	40/40	49/31	51.02 ± 9.27/49.16 ± 7.28	6	1.25 ± 1.24/1.34 ± 1.29	TG	Prednisone
Lai Lijun [43]	2019	NS	29/29	36/22	50.45 ± 1.83/49.12 ± 1.97	3	1.27 ± 0.11/1.35 ± 1.02	TG	Prednisone
Luo Zhimou [44]	2014	NS	44/30	—	47.28 ± 3.17/47.28 ± 3.17	6	3.4 ± 0.3	TG	CTX
Liu Shusheng [45]	2014	NS	50/50	53/47	1.5–14/2–13	12	—	TG	Hormone
Zhou Huiqing [46]	2014	NS	50/50	56/44	34.3 ± 1.2	12–18	2.1 ± 0.1	TG	Prednisone
Lv Lihua [47]	2017	NS	20/20	24/16	63.14 ± 9.07/62.32 ± 8.08	12	6.2 ± 1.4/5.3 ± 1.8	TG	Prednisone
Zhang Baoguo [48]	2019	NS	30/30	37/23	51.02 ± 5.84/51.06 ± 5.99	12	—	TG	Prednisone
Liu Yi [49]	2017	RNS	42/42	48/36	36.72 ± 5.41/37.12 ± 5.83	12	3.26 ± 1.18/3.45 ± 1.27	TG	Prednisone
Zhang Tingting [50]	2018	RNS	31/31	34/28	54.21 ± 3.74/55.09 ± 3.48	3	—	LEFT + TG	CTX + prednisone
Liu Qian [51]	2016	RNS	30/30	25/35	36.9 ± 4.3/36.6 ± 4.2	6	9.9 ± 3.1/9.5 ± 3.6	TG + MMF	Routine + CTX + hormone
Niu Qing [52]	2017	RNS	45/45	47/43	63.25 ± 3.21/64.25 ± 4.23	3	8.2 ± 3.2/8.6 ± 3	TG	CTX
Guo Yong [53]	2018	RNS	30/30	33/27	56.4 ± 11.2/57.1 ± 12.3	6	3.7 ± 1.1/3.6 ± 1.2	LEFT + TG	CTX + prednisone
Guo Xiaoping [54]	2017	RNS	85/85	88/82	35.19 ± 5.98/36.54 ± 6.07	4	1.01 ± 0.23/0.92 ± 0.22	TG	MMF
Wan Lin [55]	2015	RNS	104/84	122/65	51.8 ± 12.2/45.3 ± 11.8	1	—	TG	Dexamethasone
Jiao Linjuan [56]	2020	RNS	53/53	57/49	36.19 ± 4.82/35.48 ± 4.5	12	3.17 ± 0.42/3.24 ± 1.06	TG	Prednisone acetate
Chen Hui [57]	2015	RNS	42/40	36/46	34.7 ± 6.2/35.1 ± 6.7	6	0.82 ± 0.38/0.85 ± 0.4	TG	Routine + prednisone + MMF
Xu Hua [58]	2019	RNS	31/31	51/11	39.68 ± 3.27/35.97 ± 3.45	6	0.83 ± 0.11/0.83 ± 0.12	TG	MMF
Wang Xiaoxue [59]	2016	RNS	40/40	47/33	34.9 ± 7.6/35.6 ± 6.4	3	3.5 ± 1.4/3.7 ± 1.3	TG	Prednisone
Wang Maohe [60]	2014	RNS	33/33	36/30	35.1 ± 2.7/34.6 ± 2.4	12	3.5 ± 2.1/3.6 ± 1.9	TG	Prednisone
Xu Qingyun [61]	2016	RNS	40/40	47/33	39.3 ± 27.9/45.1 ± 36.9	2	6.2 ± 5.9/5.8 ± 4.7	TG	Glucocorticoid
Fan Deyong [62]	2014	RNS	48/48	53/43	34.6 ± 7.4/35.2 ± 7.8	12	3.2 ± 1.2/3.3 ± 1.3	TG	Basic + prednisone
Xia Sufang [63]	2017	PNS	71/71	79/63	76.5 ± 3.2/72.6 ± 2.3	6	—	TG	Prednisone
Wang Yongqing [64]	2014	PNS	17/17	18/16	51.12 ± 10.39	2	—	TG	Prednisone
Li Han [65]	2017	PNS	47/47	46/48	68.21 ± 1.79/67.45 ± 1.54	2	0.83 ± 0.089/0.82 ± 0.094	TG	Prednisone
Jiang Ganru [66]	2014	PNS	32/28	34/26	56.4 ± 12/55.4 ± 11.2	6	2.13 ± 0.42/2.21 ± 0.38	LEFT + TG + prednisone	CTX + prednisone
Bao Yu [67]	2013	PNS	36/36	48/24	69.2 ± 8.06	>6	0.74 ± 0.45	TG	Prednisone
Tian Junwei [68]	2017	PNS	140/140	151/129	72.19 ± 9.45/71.34 ± 9.28	2	2.92 ± 1.12/2.87 ± 1.15	TG	Prednisone + CTX
Lou Xuehang [69]	2014	PNS	19/22	24/17	60.6 ± 1.6/62.1 ± 5.8	12	—	TG + hormone	CTX + hormone
Zhu Junli [70]	2020	PNS	44/44	47/41	71.96 ± 8.63	3	1.99 ± 0.96	TG	Regular + benazepril
Zhang Qian [71]	2019	PNS	51/51	48/54	71.02 ± 9.44/72.13 ± 8.76	2	2.47 ± 0.34/2.56 ± 0.37	TG	Regular + ramipril
Ning Xiaoli [72]	2019	PNS	44/44	52/36	49.53 ± 7.11	3	—	TG	Hormone + LEFT
Xu Xiaoqin [73]	2020	PNS	35/35	45/25	43.21 ± 5.16/43.23 ± 5.15	3	5.08 ± 0.36/5.06 ± 0.35	TG	Prednisone
Jiang Liangyan [74]	2013	PNS	41/41	47/34	69.11 ± 5.51	9–12	1.34 ± 0.7	TG	Prednisone
Chen Weiwei [75]	2013	PNS	32/32	44/20	67.7 ± 5.6	12–18	0.4 ± 0.21	TG	Prednisone
Chen Yuanshu [76]	2018	PNS	38/38	44/32	48.87 ± 8.09/49.76 ± 8.21	3	2.41 ± 0.82/2.32 ± 0.76	TG	Prednisone acetate tablets + basic
Xu Junsan [77]	2017	PNS	48/46	49/45	73.47 ± 4.31/73.81 ± 4.58	12	—	TG	CTX
Li Weichao [78]	2013	PNS	15/15	17/13	29.3 ± 3.8	6	—	TG	Prednisone
Zhou Zhenzhong [79]	2015	PNS	20/20	23/17	65.23 ± 8.23/64.84 ± 7.42	4	0.79 ± 0.36/0.77 ± 0.44	TG	Prednisone
Li Xiaohong [80]	2015	PNS	40/40	47/33	53.5 ± 3.1/54 ± 3.3	—	1.6 ± 0.1/1.7 ± 0.2	TG	Prednisone + CTX
Liu Jinping [81]	2016	PNS	38/38	42/34	54.2 ± 3.7/54.1 ± 4.1	12	1.4 ± 1/1.5 ± 0.1	TG	Prednisone + CTX
Yang Yonglin [82]	2018	MN	47/44	52/39	66.62 ± 4.19/66.21 ± 3.98	6	—	TG	Benazepril
Qu Wei [83]	2016	MN	28/28	20/36	45.07 ± 11.93/38.82 ± 12.58	12	—	TG	Losartan potassium tablets
Mo Yaomei [84]	2019	MN	21/21	23/19	50.2 ± 9.08/49.8 ± 10.16	6	—	TG	Basics + MMF + prednisone
chen Ye [85]	2018	IgAN	25/24	33/16	9.3 ± 1.2/9.1 ± 1.1	3	—	Basic + prednisone + TG	Basic + prednisone

Note. T represents the experimental group and C represents the control group. M means male and F means female. “—” indicates that it is not reported or does not need to be reported. Drug dosage: glucocorticoid, 1 mg/(kg·d); (methyl)prednisone, 1–1.5 mg/kg·d; TG, 1–1.5 mg/kg·d; CTX, 8 mg/(kg·d); dipyridamole, 50 mg/time. Other drug dosages are not indicated in the literature.